Interventional2022-12-16T17:04:01+03:00
Studies on…
sepsis and severe infections
systemic inflammatory disorders
1December, 2017

ACTIVATE

December 1st, 2017|Tags: |

Completed study Official Study Title A randomized Clinical Trial for enhanced trained Immune responses through bacillus calmette-guérin VAccination to prevenT infections of the Elderly (ACTIVATE) Brief Description ACTIVATE is a randomized clinical trial aiming to investigate if the developing concept of trained immunity i.e. the memory of the innate immune system coming after vaccination

1December, 2017

INCLASS

December 1st, 2017|Tags: , |

Completed study Official Study Title A double-blind, randomized, placebo-controlled clinical study of the efficacy of INtravenous CLArithromycin as adjunctive treatment in patients with Sepsis and respiratory and multiple organ dysfunction Syndrome Brief Description INCLASS is a randomized clinical trial aiming to compare the efficacy of intravenous clarithromycin over placebo in patients with sepsis and

1October, 2017

PROGRESS

October 1st, 2017|Tags: , |

Completed study Official Study Title A randomized prospective clinical trial to assess the role of PROcalcitonin-Guided antimicrobial therapy to REduce long-term infectionS Sequelae Brief Description PROGRESS is a randomized clinical trial aiming to test the efficacy of an algorithm of the duration of antimicrobial treatment based on serum procalcitonin in patients with sepsis on

1December, 2016

IFX-1-P2.3

December 1st, 2016|Tags: |

Completed study Official Study Title An Open Label Phase II Trial to Evaluate the Safety of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa Details Status: Completed Study Type: Interventional (Clinical Trial) Study phase: II Study sites:  1 site in Greece Actual enrolment: 12 participants ClinicalTrials.gov Identifier: NCT03001622 EudraCT number: 2016-002988-33 National

1December, 2015

HIDRA04

December 1st, 2015|Tags: |

Completed study Official Study Title A double-blind, randomised, placebo-controlled clinical trial of the safety and efficacy of MABp1, a- first-in-class true human antibody targeting interleukin-1alpha, in patients with hidradenitis suppurativa not eligible for adalimumab Brief Description HIDRA04 is a double-blind randomized study aiming to the comparison of the efficacy of MABp1 (Bermekimab), a fully

1November, 2014

AIDA

November 1st, 2014|Tags: |

Completed study Official Study Title A prospective, open label, randomized controlled clinical trial, with pharmacokinetic-pharmacodynamic validation, to compare antimicrobial treatment with oral minocycline plus rifampicin to treatment with oral linezolid for complicated skin and skin structure infections (cSSSI) caused by methicillin-resistant Staphylococcus aureus (MRSA) Brief Description The AIDA consortium is a European Consortium funded

Go to Top